Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Salivary Gland Infection Market

ID: MRFR/Pharma/2506-HCR
76 Pages
Vikita Thakur
Last Updated: April 24, 2026
Salivary gland infection is one of the most common medical condition across the globe. These infections are mostly caused due to bacteria or viruses. Salivary gland infection affects salivary duct or gland.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Diagnosis (USD Billion) | |
      1. 4.1.1 Plain radiography | |
      2. 4.1.2 Sialography | |
      3. 4.1.3 High-resolution ultrasonography | |
      4. 4.1.4 Computed tomography (CT) | |
      5. 4.1.5 Magnetic Resonance Imaging (MRI) | |
      6. 4.1.6 Radionuclide scintigraphy | |
      7. 4.1.7 Others |
    2. 4.2 Healthcare, BY Treatment (USD Billion) | |
      1. 4.2.1 Medication | |
      2. 4.2.2 Surgery | |
      3. 4.2.3 Aspiration | |
      4. 4.2.4 Home care | |
      5. 4.2.5 Others |
    3. 4.3 Healthcare, BY End User (USD Billion) | |
      1. 4.3.1 Hospitals & Clinics | |
      2. 4.3.2 Medical Research Centers | |
      3. 4.3.3 Academic Institutes | |
      4. 4.3.4 Others |
    4. 4.4 Healthcare, BY Region (USD Billion) | |
      1. 4.4.1 North America | | |
        1. 4.4.1.1 US | | |
        2. 4.4.1.2 Canada | |
      2. 4.4.2 Europe | | |
        1. 4.4.2.1 Germany | | |
        2. 4.4.2.2 UK | | |
        3. 4.4.2.3 France | | |
        4. 4.4.2.4 Russia | | |
        5. 4.4.2.5 Italy | | |
        6. 4.4.2.6 Spain | | |
        7. 4.4.2.7 Rest of Europe | |
      3. 4.4.3 APAC | | |
        1. 4.4.3.1 China | | |
        2. 4.4.3.2 India | | |
        3. 4.4.3.3 Japan | | |
        4. 4.4.3.4 South Korea | | |
        5. 4.4.3.5 Malaysia | | |
        6. 4.4.3.6 Thailand | | |
        7. 4.4.3.7 Indonesia | | |
        8. 4.4.3.8 Rest of APAC | |
      4. 4.4.4 South America | | |
        1. 4.4.4.1 Brazil | | |
        2. 4.4.4.2 Mexico | | |
        3. 4.4.4.3 Argentina | | |
        4. 4.4.4.4 Rest of South America | |
      5. 4.4.5 MEA | | |
        1. 4.4.5.1 GCC Countries | | |
        2. 4.4.5.2 South Africa | | |
        3. 4.4.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Johnson & Johnson (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 GlaxoSmithKline (GB) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Merck & Co. (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 AbbVie (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Bristol-Myers Squibb (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 AstraZeneca (GB) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Novartis (CH) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Sanofi (FR) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Pfizer (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY DIAGNOSIS |
    7. 6.4 US MARKET ANALYSIS BY TREATMENT |
    8. 6.5 US MARKET ANALYSIS BY END USER |
    9. 6.6 CANADA MARKET ANALYSIS BY DIAGNOSIS |
    10. 6.7 CANADA MARKET ANALYSIS BY TREATMENT |
    11. 6.8 CANADA MARKET ANALYSIS BY END USER |
    12. 6.9 EUROPE MARKET ANALYSIS |
    13. 6.10 GERMANY MARKET ANALYSIS BY DIAGNOSIS |
    14. 6.11 GERMANY MARKET ANALYSIS BY TREATMENT |
    15. 6.12 GERMANY MARKET ANALYSIS BY END USER |
    16. 6.13 UK MARKET ANALYSIS BY DIAGNOSIS |
    17. 6.14 UK MARKET ANALYSIS BY TREATMENT |
    18. 6.15 UK MARKET ANALYSIS BY END USER |
    19. 6.16 FRANCE MARKET ANALYSIS BY DIAGNOSIS |
    20. 6.17 FRANCE MARKET ANALYSIS BY TREATMENT |
    21. 6.18 FRANCE MARKET ANALYSIS BY END USER |
    22. 6.19 RUSSIA MARKET ANALYSIS BY DIAGNOSIS |
    23. 6.20 RUSSIA MARKET ANALYSIS BY TREATMENT |
    24. 6.21 RUSSIA MARKET ANALYSIS BY END USER |
    25. 6.22 ITALY MARKET ANALYSIS BY DIAGNOSIS |
    26. 6.23 ITALY MARKET ANALYSIS BY TREATMENT |
    27. 6.24 ITALY MARKET ANALYSIS BY END USER |
    28. 6.25 SPAIN MARKET ANALYSIS BY DIAGNOSIS |
    29. 6.26 SPAIN MARKET ANALYSIS BY TREATMENT |
    30. 6.27 SPAIN MARKET ANALYSIS BY END USER |
    31. 6.28 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS |
    32. 6.29 REST OF EUROPE MARKET ANALYSIS BY TREATMENT |
    33. 6.30 REST OF EUROPE MARKET ANALYSIS BY END USER |
    34. 6.31 APAC MARKET ANALYSIS |
    35. 6.32 CHINA MARKET ANALYSIS BY DIAGNOSIS |
    36. 6.33 CHINA MARKET ANALYSIS BY TREATMENT |
    37. 6.34 CHINA MARKET ANALYSIS BY END USER |
    38. 6.35 INDIA MARKET ANALYSIS BY DIAGNOSIS |
    39. 6.36 INDIA MARKET ANALYSIS BY TREATMENT |
    40. 6.37 INDIA MARKET ANALYSIS BY END USER |
    41. 6.38 JAPAN MARKET ANALYSIS BY DIAGNOSIS |
    42. 6.39 JAPAN MARKET ANALYSIS BY TREATMENT |
    43. 6.40 JAPAN MARKET ANALYSIS BY END USER |
    44. 6.41 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS |
    45. 6.42 SOUTH KOREA MARKET ANALYSIS BY TREATMENT |
    46. 6.43 SOUTH KOREA MARKET ANALYSIS BY END USER |
    47. 6.44 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS |
    48. 6.45 MALAYSIA MARKET ANALYSIS BY TREATMENT |
    49. 6.46 MALAYSIA MARKET ANALYSIS BY END USER |
    50. 6.47 THAILAND MARKET ANALYSIS BY DIAGNOSIS |
    51. 6.48 THAILAND MARKET ANALYSIS BY TREATMENT |
    52. 6.49 THAILAND MARKET ANALYSIS BY END USER |
    53. 6.50 INDONESIA MARKET ANALYSIS BY DIAGNOSIS |
    54. 6.51 INDONESIA MARKET ANALYSIS BY TREATMENT |
    55. 6.52 INDONESIA MARKET ANALYSIS BY END USER |
    56. 6.53 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS |
    57. 6.54 REST OF APAC MARKET ANALYSIS BY TREATMENT |
    58. 6.55 REST OF APAC MARKET ANALYSIS BY END USER |
    59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
    60. 6.57 BRAZIL MARKET ANALYSIS BY DIAGNOSIS |
    61. 6.58 BRAZIL MARKET ANALYSIS BY TREATMENT |
    62. 6.59 BRAZIL MARKET ANALYSIS BY END USER |
    63. 6.60 MEXICO MARKET ANALYSIS BY DIAGNOSIS |
    64. 6.61 MEXICO MARKET ANALYSIS BY TREATMENT |
    65. 6.62 MEXICO MARKET ANALYSIS BY END USER |
    66. 6.63 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS |
    67. 6.64 ARGENTINA MARKET ANALYSIS BY TREATMENT |
    68. 6.65 ARGENTINA MARKET ANALYSIS BY END USER |
    69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS |
    70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT |
    71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
    72. 6.69 MEA MARKET ANALYSIS |
    73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS |
    74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT |
    75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY END USER |
    76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS |
    77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT |
    78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY END USER |
    79. 6.76 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS |
    80. 6.77 REST OF MEA MARKET ANALYSIS BY TREATMENT |
    81. 6.78 REST OF MEA MARKET ANALYSIS BY END USER |
    82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
    83. 6.80 RESEARCH PROCESS OF MRFR |
    84. 6.81 DRO ANALYSIS OF HEALTHCARE |
    85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
    88. 6.85 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE) |
    89. 6.86 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion) |
    90. 6.87 HEALTHCARE, BY TREATMENT, 2024 (% SHARE) |
    91. 6.88 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion) |
    92. 6.89 HEALTHCARE, BY END USER, 2024 (% SHARE) |
    93. 6.90 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
    94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    95. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END USER, 2025-2035 (USD Billion) |
    97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY END USER, 2025-2035 (USD Billion) |
    98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY END USER, 2025-2035 (USD Billion) |
    99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY END USER, 2025-2035 (USD Billion) |
    100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY END USER, 2025-2035 (USD Billion) |
    101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY END USER, 2025-2035 (USD Billion) |
    102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY END USER, 2025-2035 (USD Billion) |
    103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY END USER, 2025-2035 (USD Billion) |
    104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY END USER, 2025-2035 (USD Billion) |
    105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY END USER, 2025-2035 (USD Billion) |
    106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY END USER, 2025-2035 (USD Billion) |
    107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY END USER, 2025-2035 (USD Billion) |
    108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY END USER, 2025-2035 (USD Billion) |
    109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY END USER, 2025-2035 (USD Billion) |
    110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY END USER, 2025-2035 (USD Billion) |
    111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY END USER, 2025-2035 (USD Billion) |
    112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY END USER, 2025-2035 (USD Billion) |
    113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY END USER, 2025-2035 (USD Billion) |
    114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY END USER, 2025-2035 (USD Billion) |
    115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY END USER, 2025-2035 (USD Billion) |
    116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY END USER, 2025-2035 (USD Billion) |
    117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY END USER, 2025-2035 (USD Billion) |
    118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY END USER, 2025-2035 (USD Billion) |
    119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY END USER, 2025-2035 (USD Billion) |
    120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY END USER, 2025-2035 (USD Billion) |
    121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY END USER, 2025-2035 (USD Billion) |
    122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY END USER, 2025-2035 (USD Billion) |
    123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY END USER, 2025-2035 (USD Billion) |
    124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY DIAGNOSIS, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY END USER, 2025-2035 (USD Billion) |
    125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    126. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Diagnosis (USD Billion, 2025-2035)

  • Plain radiography
  • Sialography
  • High-resolution ultrasonography
  • Computed tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Radionuclide scintigraphy
  • Others

Healthcare By Treatment (USD Billion, 2025-2035)

  • Medication
  • Surgery
  • Aspiration
  • Home care
  • Others

Healthcare By End User (USD Billion, 2025-2035)

  • Hospitals & Clinics
  • Medical Research Centers
  • Academic Institutes
  • Others